Curated News
By: NewsRamp Editorial Staff
November 11, 2025
Quantumzyme Expands AI Enzyme Platform for Green Pharma Manufacturing
TLDR
- Quantumzyme's expanded AI enzyme platform offers pharmaceutical companies a competitive edge through sustainable API manufacturing with improved cost efficiency and reduced environmental impact.
- Quantumzyme's platform uses AI-driven computational modeling, in silico directed evolution, and high-throughput validation to design optimized biocatalysts that replace traditional chemical reaction steps.
- This technology advances green pharmaceutical manufacturing by reducing hazardous waste, toxic solvent use, and carbon emissions, creating a cleaner environment for future generations.
- Quantumzyme is expanding its AI enzyme platform beyond ibuprofen to target high-volume APIs like phenylephrine using computational biology for greener drug manufacturing.
Impact - Why it Matters
This development matters because traditional pharmaceutical manufacturing generates massive environmental waste and relies heavily on toxic solvents and energy-intensive processes. As the global API market approaches $300 billion, the shift toward sustainable biocatalysis could significantly reduce industrial pollution, lower carbon emissions, and create more resilient domestic supply chains. For consumers, this means potentially safer, more environmentally friendly medications while addressing critical sustainability challenges in an industry that has historically been a major polluter.
Summary
Quantumzyme Corp., a global leader in computational enzyme engineering and digital biocatalysis, has announced a significant expansion of its AI-powered enzyme design platform to target additional high-volume Active Pharmaceutical Ingredients beyond its previously validated ibuprofen process. This strategic initiative represents a major advancement in green pharmaceutical manufacturing, leveraging the company's proprietary technology to reduce hazardous waste, toxic solvent use, and carbon emissions at industrial scale. The expansion builds upon Quantumzyme's successful enzymatic process for green ibuprofen synthesis and extends the platform's capabilities to other APIs with substantial global environmental impact.
The expanded R&D pipeline incorporates multiple high-volume APIs, including chiral intermediates such as phenylephrine and related compounds accessible via ketoreductases, which are widely utilized in the global generics sector. According to CEO Naveen Kulkarni, the global API market is projected to exceed $300 billion by 2030, with generic drugs comprising the majority of production volume. Much of this manufacturing currently relies on overseas legacy chemistries that generate heavy waste streams and carry high solvent and carbon intensity. Quantumzyme's biocatalysis-first approach offers a sustainable alternative that delivers reduced chemical waste and solvent usage, lower carbon footprint, elimination of toxic reagents, and improved cost and yield efficiency.
Quantumzyme's enzyme engineering platform integrates advanced AI-driven computational modeling, in silico directed evolution, mechanistic simulation, and high-throughput validation to develop optimized biocatalysts that replace traditional energy-intensive chemical reaction steps. The company's vision, as articulated by Kulkarni, is to redefine chemical manufacturing through sustainable innovation while supporting domestic API manufacturing and aligning with U.S. supply chain resilience and sustainability goals. For more information, interested parties can visit www.quantumzymecorp.com and the company's profile at www.otcmarkets.com/stock/QTZM, while the original release can be viewed on www.newmediawire.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Quantumzyme Expands AI Enzyme Platform for Green Pharma Manufacturing
